Trazodone Side Effects: Rare but Serious Adverse Events Explained

Why Rare Trazodone Adverse Events Still Matter Clinically

Trazodone is one of the most prescribed non-benzodiazepine sleep aids in the United States, with off-label use for insomnia accounting for the majority of its prescriptions. Because the drug is perceived as low-risk relative to benzodiazepines or z-drugs, prescribers and patients sometimes overlook a cluster of adverse events that are uncommon in absolute terms but severe when they occur. The FDA prescribing label for trazodone lists warnings for suicidality, cardiac arrhythmia, priapism, hypotension, and serotonin syndrome, each supported by post-market surveillance and case literature. [1]

Understanding which patient profiles carry the highest risk for each event is the starting point for safe prescribing.

Who Is Most Vulnerable

Older adults on multiple serotonergic or QT-prolonging drugs carry compounded risk. Men with sickle-cell disease or on phosphodiesterase-5 inhibitors face a disproportionate priapism burden. Patients with hepatic impairment accumulate trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) at higher plasma concentrations, raising the probability of both central nervous system and cardiovascular events. [2]

The mCPP Metabolite Problem

MCPP is a partial agonist at 5-HT2C receptors and contributes meaningfully to trazodone's adverse-effect profile, especially at higher doses. A pharmacokinetic study published in the Journal of Clinical Psychopharmacology found that mCPP plasma concentrations correlate with anxiety, dizziness, and the serotonergic activation that can potentiate true serotonin syndrome when a second agent is added. [3] Clinicians who increase trazodone beyond 200 mg per day should be aware that mCPP exposure rises non-linearly.

Serotonin Syndrome

Serotonin syndrome is the most acutely dangerous drug interaction risk with trazodone. It results from excess serotonergic activity at central and peripheral receptors and can progress from mild agitation to multi-organ failure within hours. The Hunter Criteria define the diagnosis around the clinical triad of neuromuscular abnormality, autonomic instability, and altered mental status. [4]

Which Combinations Trigger It

Trazodone combined with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tramadol, linezolid, or methylene blue carries the highest risk. The FDA label explicitly contraindicates trazodone within 14 days of MAOI use in either direction. [1] A 2021 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) identified serotonin syndrome as a disproportionately reported outcome when trazodone was combined with SSRIs, with a reporting odds ratio of 4.8 relative to trazodone monotherapy. [5]

Recognizing It Fast

Onset is typically within 6 hours of adding or increasing a serotonergic drug. Early signs include tremor, hyperreflexia, and diaphoresis. Clonus, especially inducible ocular clonus, is highly specific. Temperature above 41.1°C signals a medical emergency with mortality risk exceeding 25% if untreated. [4]

Cyproheptadine 12 mg orally, followed by 2 mg every two hours if symptoms persist, is the pharmacologic antidote most frequently referenced in case series, though controlled trial data are absent by the nature of the syndrome's emergency presentation. Benzodiazepines manage neuromuscular excitability. MAOIs require an ICU setting.

Priapism

Trazodone-induced priapism is the adverse event most unique to this drug among antidepressants. Estimated incidence in male patients is approximately 1 in 6,000, a figure cited in the original prescribing literature and reinforced by subsequent FAERS case counts. [1] The mechanism is alpha-1 adrenoceptor blockade in penile vasculature, which impairs detumescence independent of sexual arousal.

Time Course and Severity

Most cases occur within the first month of therapy, often during dose escalation. Erections lasting longer than 4 hours constitute a urological emergency because ischemic priapism beyond 6 hours produces irreversible corporal fibrosis and erectile dysfunction in up to 50% of affected men. [6] A case series published in the Journal of Urology found trazodone implicated in 21% of drug-induced priapism presentations at a tertiary urology center over a 10-year period. [6]

Clinical Protocol

Any erection lasting more than 2 hours warrants immediate evaluation. The American Urological Association guideline on priapism recommends intracavernosal phenylephrine (100 to 500 mcg every 3 to 5 minutes, up to 1 mg total) as the first-line treatment for ischemic priapism because it avoids the cardiovascular stimulation of epinephrine. [6] Trazodone should be permanently discontinued after a confirmed priapism episode. Patients should receive explicit written counseling before starting the drug.

Female Patients Are Not Exempt

Clitoral priapism (clitorism) has been reported in women taking trazodone, though case counts in FAERS are far lower. The mechanism mirrors the male presentation, involving alpha-1 blockade in erectile tissue. Clinicians should counsel female patients that prolonged, painful clitoral engorgement also requires urgent evaluation.

QT Prolongation and Cardiac Arrhythmia

Trazodone blocks the hERG potassium channel at higher plasma concentrations, an effect that prolongs the cardiac QT interval and can precipitate Torsades de Pointes (TdP). The CredibleMeds database classifies trazodone as a "conditional risk" agent for TdP, meaning the risk rises substantially in the presence of co-existing risk factors. [7]

Risk Factor Stacking

The following conditions each independently extend QTc and combine additively with trazodone:

• Hypokalemia or hypomagnesemia (common in patients on loop diuretics)
• Congenital long-QT syndrome
• Bradycardia below 50 bpm
• Co-administration of other QT-prolonging drugs (azithromycin, haloperidol, methadone, ondansetron)
• Trazodone doses above 200 mg per day

A 2019 retrospective analysis in the Journal of Cardiovascular Electrophysiology found that trazodone use was associated with a mean QTc increase of 11.5 ms (95% CI 7.2 to 15.8 ms) in hospitalized patients, with the effect most pronounced when trazodone was combined with a second QT-prolonging agent. [8]

Monitoring Recommendations

Obtain a baseline ECG before starting trazodone in any patient who is older than 65 years, has cardiac disease, is hypokalemic, or is on one or more QT-prolonging drugs. Repeat the ECG after reaching a stable dose. Correct electrolyte abnormalities before initiation. If QTc exceeds 500 ms or rises more than 60 ms from baseline, trazodone should be stopped and cardiology consulted.

Hepatotoxicity

Clinically significant trazodone hepatotoxicity is rare, but the pattern that emerges from case literature is worth recognizing: a mixed hepatocellular-cholestatic injury appearing 1 to 26 weeks after starting the drug. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) LiverTox database, which draws on published case reports and FAERS, assigns trazodone a likelihood score of B, indicating probable causality in reported hepatotoxic reactions. [9]

What the Case Literature Shows

A case series of eight patients published in the Annals of Internal Medicine described trazodone-associated liver injury with peak alanine aminotransferase (ALT) values ranging from 5 to 40 times the upper limit of normal. [10] Six of the eight cases resolved within 8 weeks of drug discontinuation. One patient progressed to acute liver failure requiring transplant evaluation. Autoimmune markers (ANA, smooth-muscle antibody) were elevated in three cases, suggesting an immune-mediated component in a subset. [10]

Identifying the Signal Early

Symptoms preceding laboratory elevation include right upper quadrant discomfort, fatigue, and jaundice. Monitoring AST and ALT at baseline and at 6 to 12 weeks in patients with pre-existing hepatic disease or alcohol use disorder is a reasonable clinical precaution, though no guideline has yet formalized this interval. If ALT exceeds three times the upper limit of normal with symptoms, trazodone should be stopped and the workup for drug-induced liver injury (DILI) initiated per the DILIN protocol. [9]

Orthostatic Hypotension and Syncope

Alpha-1 adrenoceptor blockade does not stop at penile vasculature. Systemic vasodilation reduces standing blood pressure, and trazodone's half-life of 5 to 9 hours means the effect peaks in the middle of the night when patients rise to use the bathroom. Syncope and fall-related injuries are the main clinical consequences, particularly in older adults.

Fall Risk in Older Patients

A large pharmacoepidemiology study using Medicare claims data found that trazodone initiation was associated with a 1.67-fold increase in hip fracture risk in adults older than 65 years during the first 30 days of therapy, a window consistent with the drug's peak hypotensive effect before tolerance partially develops. [11] This figure places trazodone in a similar risk category to other sedating drugs with alpha-blocking properties.

Dose Timing Strategies

Administering trazodone 30 to 60 minutes before bed and keeping the dose at or below 100 mg for sleep indications reduces the magnitude of orthostatic drop. Patients should be counseled to sit on the edge of the bed for 30 seconds before standing. Concurrent use of antihypertensives, especially alpha-blockers such as tamsulosin, compounds the risk and may require a dose reduction or drug substitution.

Suicidality: The FDA Black-Box Warning

The FDA's 2007 black-box warning on all antidepressants, including trazodone, mandates disclosure of increased suicidal thinking and behavior in patients under 25 years of age. [1] The signal emerged from a pooled analysis of 24 placebo-controlled trials (N = 4,400 pediatric patients) submitted to the FDA, which found a relative risk of 1.95 for suicidal ideation or behavior on active drug versus placebo in the first 1 to 4 weeks of treatment. [12]

Trazodone is rarely used as a primary antidepressant today, but it is sometimes added to an antidepressant regimen for sleep augmentation, which means young patients on SSRIs may also be taking trazodone. Monitoring frequency in the first 4 weeks should match FDA guidance: weekly contact for weeks 1 to 4, biweekly for weeks 5 to 8, and monthly thereafter.

Hyponatremia

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) leading to hyponatremia has been documented with trazodone, though it is less commonly recognized than with SSRIs. The mechanism involves serotonin-mediated stimulation of antidiuretic hormone release. A FAERS disproportionality analysis published in Drug Safety in 2017 identified trazodone as a significant signal for SIADH, with a reporting odds ratio of 3.1 (95% CI 1.9 to 5.1). [13]

Older adults, women, and patients on thiazide diuretics are at highest risk. Serum sodium below 125 mmol/L warrants drug discontinuation and may require hypertonic saline if the patient is symptomatic. Sodium should be corrected at a rate no faster than 10 to 12 mmol/L per 24 hours to avoid osmotic demyelination syndrome.

Withdrawal and Discontinuation Syndrome

Trazodone discontinuation syndrome is less studied than SSRI discontinuation syndrome but is documented in case reports and patient registries. Symptoms include rebound insomnia, irritability, anxiety, and dizziness, typically appearing 2 to 4 days after abrupt cessation and resolving within 1 to 2 weeks. [14]

A taper of 25 to 50 mg per week is a commonly used clinical approach, though no randomized trial has established the optimal schedule. The FINISH mnemonic (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) applies partially to trazodone but sensory disturbances such as "brain zaps" are less frequently reported compared to SSRIs or venlafaxine. [14]

Angle-Closure Glaucoma

Pupillary dilation from serotonergic activity can precipitate acute angle-closure glaucoma in anatomically predisposed eyes. Trazodone's anticholinergic contribution is minimal compared to tricyclic antidepressants, but serotonin-mediated mydriasis is sufficient to trigger acute closure in patients with narrow anterior chamber angles. [15]

Symptoms are acute: severe eye pain, blurred vision, and halos around lights. An intraocular pressure above 21 mmHg in this context is a same-day ophthalmology referral. Patients who have already undergone laser peripheral iridotomy are protected and can take trazodone without this concern.

A Decision Framework for Risk Stratification Before Prescribing Trazodone

The table below organizes the rare but serious adverse events by the patient characteristic that most amplifies each risk. Clinicians can use it as a pre-prescription checklist before initiating trazodone, particularly in complex or elderly patients.

| Adverse Event | Highest-Risk Patient Profile | Pre-Prescription Action | |---|---|---| | Serotonin syndrome | On SSRI, SNRI, MAOI, tramadol, or linezolid | Review full medication list; consider dose ceiling of 100 mg | | Priapism | Male, sickle-cell disease, on PDE-5 inhibitor | Explicit written counseling; start at lowest effective dose | | QT prolongation / TdP | Hypokalemia, cardiac disease, on QT-prolonging drug | Baseline ECG; correct electrolytes before starting | | Hepatotoxicity | Pre-existing liver disease, alcohol use disorder | Baseline AST/ALT; recheck at 6 to 12 weeks | | Orthostatic hypotension / falls | Age >65, on antihypertensives or alpha-blockers | Bed-time dosing at 50 mg; fall precautions counseling | | Suicidality | Age <25, history of suicidal ideation | Weekly monitoring weeks 1 to 4 per FDA guidance | | Hyponatremia | Age >65, female, on thiazide diuretics | Baseline sodium; recheck at 2 to 4 weeks | | Angle-closure glaucoma | Narrow anterior chamber angle, family history | Ophthalmology clearance or confirm prior iridotomy |